Floatz logo

MICAFUNGIN

Febrile Neutropenia

Wake Forest University Health SciencesSmall moleculePhase 4 / ApprovedActive
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Febrile Neutropenia cohort.

Asset / SponsorPhaseRating
Pegylated Rhg-Csf
Jiangsu HengRui Medicine Co., Ltd.
Phase 3BB
Rhgm-Csf
Jiangsu HengRui Medicine Co., Ltd.
Phase 3BB
Conjugated Pneumococcal Vaccine
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Phase 4BB
L-Ofloxacin
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Phase 4BB
PEGFILGRASTIM
Asan Medical Center
Phase 3BB

View all 16 →

Same molecule, other indications

MICAFUNGIN is also rated in:

nutritional deficiency diseaseDormant
B
Indicative ·
61 / 100
View asset →
morbid obesityDormant
B
Indicative ·
60 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →